A data-driven approach to Container Closure Integrity

Selecting container closure components with confidence:A data-driven approach to Container Closure Integrity.

There are few signs that momentum in the biologics market is set to slow down. Strong pipeline growth and a dominant share of drug approvals by the US Food & Drug Administration (FDA) in recent years points to the sector’s sustained potential for years to come. Bringing a new drug to market can undoubtedly deliver great rewards for patients and patent-holders alike, but whether in the case of biologics or small molecules, it is an undertaking that also carries well-documented risks.

Read more